Renal Cancer - Results from #1540

Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. April 11, 2022

Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. April 11, 2022

Screening programs for renal cell carcinoma: a systematic review by the EAU young academic urologists renal cancer working group. April 8, 2022

GRade, Age, Nodes, and Tumor (GRANT) compared with Leibovich score to predict survival in localized renal cell carcinoma: A nationwide study. April 8, 2022

Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up. April 7, 2022

Device-related complications during renal cryoablation: insights from the Manufacturer and User Facility Device Experience (MAUDE) database. April 7, 2022

Construction and validation of a prognostic model for kidney renal clear cell carcinoma based on podocyte-associated genes. April 6, 2022

Systematic Analysis of the Expression and Prognosis of Fcγ Receptors in Clear Cell Renal Cell Carcinoma. April 6, 2022

99m Tc sestamibi SPECT/CT in the prediction of malignant versus benign small renal masses. April 5, 2022

Biomarkers of the transsulfuration pathway and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. April 5, 2022

Tumor Size Significantly Affects Prognosis in Pathological T3a Renal Cell Carcinoma. April 4, 2022

Adipogenic Transdifferentiation and Regulatory Factors Promote the Progression and the Immunotherapy Response of Renal Cell Carcinoma: Insights From Integrative Analysis. April 4, 2022

Evaluation of PD-L1 (E1L3N, 22C3) expression in venous tumor thrombus is superior to its assessment in renal tumor in predicting overall survival in renal cell carcinoma. April 1, 2022

Robotic partial nephrectomy for management of renal mass in patients with a solitary kidney: can we expand the indication to T2 and T3 disease? April 1, 2022

Impact of Trifecta definition on rates and predictors of "successful" robotic partial nephrectomy for localized renal masses: results from the Surface-Intermediate-Base Margin Score International Consortium. April 1, 2022

Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors. March 31, 2022

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. March 31, 2022

The radiomics-based tumor heterogeneity adds incremental value to the existing prognostic models for predicting outcome in localized clear cell renal cell carcinoma: a multicenter study. March 30, 2022

Oncologic Outcomes of Renal Cell Carcinoma Patients Undergoing Radical Nephrectomy and Venous Thrombectomy: Prospective Follow-Up from a Single Center. March 30, 2022

Comparison of the Results of Therapy for cT1 Renal Carcinoma with Nephron-Sparing Surgery (NSS) vs. Percutaneous Thermal Ablation (TA). March 29, 2022

Page 78 of 456